Navigation Links
Rafarma Pharmaceuticals Announces a $1.2 Million Private Placement
Date:12/12/2013

MOSCOW, Dec. 12, 2013 /PRNewswire/ -- Rafarma Pharmaceuticals (OTC:RAFA), announces a $1.2 million private placement.  

A $1.2 million private placement has been closed with a share price of $0.65 per share.  Proceeds from this private placement are being applied to company expansion and to reduce commercial debt.

Stated CEO Dave Anderson: "As Rafarma continues to develop new manufacturing partners, we anticipate that this private placement is just the beginning of a vibrant private financing market for the pharmaceutical sector. We are pleased with the investor enthusiasm in Rafarma's potential."

The securities offered in the private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The securities were offered only to accredited investors.

About Rafarma Pharmaceuticals, Inc.

Operating from a new 270,000 square-foot state-of-the-art manufacturing and distribution facility in Russia, Rafarma Pharmaceuticals produces generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products that are approved by the Ministry of Health of Russian Federation. For the last three years, the Russian Government has been highly focused on bolstering the development of the nation's domestic pharmaceutical industry. Rafarma Pharmaceuticals' mission is to work with the auspices of aggressive federal initiatives to fast-track the modernization of Russia's pharmaceutical industry.

For more information on Rafarma Pharmaceuticals, visit: http://rafarma.com

Safe Harbor Statement

Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance.

RELATED LINKS
Website: www.Rafarma.com
Facebook: www.facebook.com/Rafarmainfo
Twitter: www.twitter.com/Rafarmainfo

Contact: David Anderson, info@rafarma.com


'/>"/>
SOURCE Rafarma Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Rafarma Pharmaceuticals, Inc. Named 1 Of 4 National Strategic Pharmaceutical Suppliers To The Russian Federation
2. Rafarma Pharmaceuticals, Inc. Receives General License for Pharmaceutical Products and has Started to Manufacture 3 New Products
3. Rafarma Pharmaceuticals, Inc. (RAFA) announces plans for PCAOB-Registrant Audit and Streamlining of Corporate Structure to Upgrade Market Listing.
4. Rafarma Pharmaceuticals, Inc. (RAFA) Joins in Economic Development Coalition to Increase Biotech Growth in Terbuny, Russia.
5. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
6. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
7. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
8. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
9. Icahn Issues Statement Regarding Amylin Pharmaceuticals
10. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
11. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... NEW YORK , Jan. 23, 2017 MouthWatch ... Intraoral Camera was ranked as the best intraoral camera ... , taking the #2 spot overall. The #1 product was ... DentalCompare.com said the MouthWatch intraoral camera was "…incredibly popular because ... while the camera has a small sticker price, it doesn,t ...
(Date:1/23/2017)... 2017  Delcath Systems, Inc. (NASDAQ: DCTH ... of primary and metastatic liver cancers, today announced that ... and Chief Executive Officer of Delcath will be a ... Thirteenth Annual Investor Conference at the Boca Raton Resort ... , on Tuesday, January 31, 2017 at 10:30 am ...
(Date:1/23/2017)... SAN DIEGO , Jan. 23, 2017 /PRNewswire/ ... identify patients at high risk for acute kidney ... treatment recommended by globally-recognized care guidelines ... moderate to severe AKI more than 33 percent, ... weekend in the journal Intensive Care Medicine. ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... ... Mill”: a story of love and redemption, hope and uncertainty as a girl makes ... “The Inn at the Mill” is the creation of published author, Lois Kulp, who was ... in Berks County on Crow Hill. The inn, the mill and "Post Yokel" ...
(Date:1/23/2017)... ... ... Infallible Characteristics of Christ”: a fascinating and entrancing novel exploring the gifts and ... author, Rev. Dr. Robert W. Thomas, the third of seven siblings. He was a ... pastor for over fifteen years. He is a graduate of N.C. College of Theology ...
(Date:1/22/2017)... California (PRWEB) , ... January 22, 2017 , ... "Photo ... Cloud to create a beautiful 3D slideshow with complete ease," said Christina Austin - ... Generators browser to place in the FCPX timeline. Presets include scenes with ...
(Date:1/21/2017)... ... 21, 2017 , ... "ProDOF is the perfect set of tools for video editors that want ... scene," said Christina Austin - CEO of Pixel Film Studios. , Video editors using ... illusion of a DSLR racking focus from one area into the next. ProDOF comes ...
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... ... Redwood Family Dermatology has recently joined their multi-specialty medical group. The ... range of cosmetic services. , “We’re excited to add this excellent dermatology practice ...
Breaking Medicine News(10 mins):